ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Swelling	08.01.03.015	0.000426%		Not Available
Swelling face	08.01.03.100; 23.04.01.018; 10.01.05.018	0.000531%		Not Available
Swollen tongue	23.04.01.014; 10.01.05.015; 07.14.02.003	0.000210%		Not Available
Syncope	02.11.04.015; 24.06.02.012; 17.02.04.008	-	-
Synovial cyst	16.18.01.004; 15.04.02.002	0.000052%		Not Available
Synovitis	15.04.02.001	0.000140%		Not Available
Systemic lupus erythematosus	15.06.02.003; 10.04.03.004; 23.03.02.006	0.000280%		Not Available
Tachycardia	02.03.02.007	0.000734%		Not Available
Tachycardia foetal	18.03.02.005; 02.03.02.017	0.000035%		Not Available
Tachypnoea	22.02.01.014	0.000070%		Not Available
Tearfulness	19.15.02.005	0.000035%		Not Available
Telangiectasia	24.03.03.003; 23.06.03.001	0.000035%
Tendon disorder	12.01.07.019; 15.07.01.002	0.000070%		Not Available
Tendon rupture	12.01.07.003; 15.07.01.008	-	-	Not Available
Tendonitis	15.07.01.003; 12.01.07.007	0.000210%		Not Available
Tenosynovitis	15.07.01.004	0.000087%		Not Available
Therapeutic response decreased	08.06.01.016	0.000262%		Not Available
Therapeutic response unexpected	08.06.01.001	0.000182%		Not Available
Thrombocytopenia	01.08.01.002	0.001800%		Not Available
Thrombocytosis	01.08.02.001	0.000164%		Not Available
Thrombophlebitis	24.01.02.001	-	-	Not Available
Thrombotic microangiopathy	24.01.01.013; 20.01.07.004; 01.01.02.006	0.000262%		Not Available
Thrombotic thrombocytopenic purpura	24.07.06.014; 23.06.01.011; 01.08.01.005	0.000070%
Thyroiditis	05.02.04.001	0.000070%		Not Available
Tinnitus	04.04.01.002; 17.04.07.004	0.000210%
Tooth loss	12.01.17.026; 07.09.09.001	0.000105%		Not Available
Toothache	07.09.06.001	0.000087%
Toxic encephalopathy	17.13.01.004; 12.03.01.027	0.000052%		Not Available
Toxic epidermal necrolysis	12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008	0.000105%
Transplant rejection	12.02.05.022; 10.02.03.002	0.000140%		Not Available

The 21th Page First Pre 21 22 23 24 25 Next Last Total 36 Pages